News

Phase 2 Clinical Trial Results of Telacebec Published in NEJM

On March 25th, Qurient announced the results of their Phase 2 Clinical Trial  (ClinicalTrials.gov number, NCT03563599), which was a prospective, randomized, open-label trial for proof of concept in humans of their novel anti-tuberculosis drug, Telacebec (Q203). The trial involved 61 newly-diagnosed patients with drug-susceptible pulmonary tuberculosis. Patients received a dose of 100 mg, 200 mg, or 300 mg once daily or combination therapy with rifampin, isoniazid, pyrazinamide, and ethambutol (RHZE) as reported in the New England Journal of Medicine. According to the article, increasing doses of telacebec were associated with greater reductions in time to positivity of collected sputum samples, which they used to determine bactericidal activity. 

To read more about this latest trial by Qurient, take a look at their press release on Business Wire or their article published in the New England Journal of Medicine

More News
29 Jul 2020
The WGND is announcing a call for applications to become a part of the WGND Core Group (CG). The CG provides leadership and sets the strategic direction for the work of the WGND. Addmitted applicants will begin their term in September 2020. Current CG membership information is available on the WGND...
9 Jul 2020
Earlier this week, Johnson & Johnson announced a reduction in the price for bedaquiline in low- and middle-income countries, as part of a collaboration with the Stop TB Partnership's Global Drug Facility (GDF). The immediate change in price will make bedaquiline available through the GDF at the...
18 Jun 2020
On May 21st, Antimicrbial Agents and Chemotherapy published an article on Otsuka's novel anti-tuberculosis compound, OPC-167832. This molecule, a DprE1 inhibitor, demonstrated potent bactericidal activity and exhibited significant combination effects in 2-drug combinations with delamanid,...